Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1Interstate Cannabis

AYLA Insider Trading (Ayala Pharmaceuticals)

Insider Ownership Percentage: 2.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $954,801.36

Ayala Pharmaceuticals Insider Trading History Chart

Ayala Pharmaceuticals Share Price & Price History

$11.21
▼ -0.09 (-0.80%)
As of 06/18/2021 01:00 AM ET
Days: 30 | 90 | 365
Facebook Billionaire Investing in a Shocking New Industry
Peter Thiel, the billionaire investor behind Facebook, PayPal, and eBay, has a new darling industry in his sights. And he's betting a massive $210 million on its success. That's not pocket change.
And today, you could get in on the ground floor

Ayala Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/24/2021Roni MamlukCEOSell33,126$18.63$617,137.38
1/20/2021Gary B GordonInsiderSell3,000$15.03$45,090.0011,520View SEC Filing Icon  
1/20/2021Roni MamlukCEOSell19,466$15.03$292,573.98179,877View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Ayala Pharmaceuticals (NASDAQ:AYLA)

15.45% of Ayala Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Ayala Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/18/2021Millennium Management LLC12,407$0.14M0.0%-41.2%0.094%Search for SEC Filing on Google Icon
5/18/2021Opaleye Management Inc.108,551$1.18M0.2%N/A0.820%Search for SEC Filing on Google Icon
5/18/2021Morgan Stanley4,173$46K0.0%N/A0.032%Search for SEC Filing on Google Icon
4/22/2021Chevy Chase Trust Holdings Inc.15,000$0.16M0.0%N/A0.114%Search for SEC Filing on Google Icon
10/30/2020ARK Investment Management LLC12,063$0.14M0.0%N/A0.094%Search for SEC Filing on Google Icon
8/14/2020Jefferies Group LLC800,000$8.08M0.1%N/A6.260%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Ayala Pharmaceuticals logo
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Read More on Ayala Pharmaceuticals

Today's Range

Now: $11.21
$11.01
$11.84

50 Day Range

MA: $10.16
$9.20
$11.30

52 Week Range

Now: $11.21
$8.62
$28.68

Volume

6,500 shs

Average Volume

24,899 shs

Market Capitalization

$148.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Ayala Pharmaceuticals?

Ayala Pharmaceuticals' top insider investors include:
  1. Roni Mamluk (CEO)
  2. Gary B Gordon (Insider)

Who are the major institutional investors of Ayala Pharmaceuticals?

Ayala Pharmaceuticals' top institutional shareholders include:
  1. Opaleye Management Inc. — 0.82%
  2. Chevy Chase Trust Holdings Inc. — 0.11%
  3. Millennium Management LLC — 0.09%
  4. Morgan Stanley — 0.03%

Which institutional investors are selling Ayala Pharmaceuticals stock?

In the previous quarter, AYLA stock was sold by these institutional investors:
  1. Millennium Management LLC
During the last year, company insiders that have sold Ayala Pharmaceuticals company stock include:
  1. Roni Mamluk (CEO)
  2. Gary B Gordon (Insider)

Which institutional investors are buying Ayala Pharmaceuticals stock?

Within the last quarter, AYLA stock was purchased by institutional investors including:
  1. Opaleye Management Inc.
  2. Chevy Chase Trust Holdings Inc.
  3. Morgan Stanley
Facebook Billionaire Investing in a Shocking New Industry
Peter Thiel, the billionaire investor behind Facebook, PayPal, and eBay, has a new darling industry in his sights. And he's betting a massive $210 million on its success. That's not pocket change.
And today, you could get in on the ground floor